Click for best price
Myasthenia Gravis Drugs Market Size, Share 2022
This report contains market size and forecasts of Myasthenia Gravis Drugs in global, including the following market information:
Global Myasthenia Gravis Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Myasthenia Gravis Drugs Market Sales, 2017-2022, 2023-2028, (MT)
Global top five Myasthenia Gravis Drugs companies in 2021 (%)
The global Myasthenia Gravis Drugs market was valued at 1467.3 million in 2021 and is projected to reach US$ 2400 million by 2028, at a CAGR of 7.3% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Anticholinesterases Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Myasthenia Gravis Drugs include Flamel Technologies, F. Hoffmann-La Roche, Grifols, Pfizer, Takeda, Novartis, Bausch Health, Alexion Pharmaceuticals and Catalyst Pharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Myasthenia Gravis Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Myasthenia Gravis Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (MT)
Global Myasthenia Gravis Drugs Market Segment Percentages, by Type, 2021 (%)
Anticholinesterases
Immunosuppressants
Intravenous Immune Globulins
Global Myasthenia Gravis Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (MT)
Global Myasthenia Gravis Drugs Market Segment Percentages, by Application, 2021 (%)
Hospitals
Clinics
Global Myasthenia Gravis Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (MT)
Global Myasthenia Gravis Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Myasthenia Gravis Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Myasthenia Gravis Drugs revenues share in global market, 2021 (%)
Key companies Myasthenia Gravis Drugs sales in global market, 2017-2022 (Estimated), (MT)
Key companies Myasthenia Gravis Drugs sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Flamel Technologies
F. Hoffmann-La Roche
Grifols
Pfizer
Takeda
Novartis
Bausch Health
Alexion Pharmaceuticals
Catalyst Pharmaceuticals
CSL
Curavac
Cytokinetics
Galencia
GlaxoSmithKline
Lupin Pharmaceuticals
Mitsubishi Tanabe Pharma
| Report Attributes |
Report Details |
| Report Title |
Myasthenia Gravis Drugs Market, Global Outlook and Forecast 2022-2028 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
117 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Myasthenia Gravis Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Myasthenia Gravis Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Myasthenia Gravis Drugs Overall Market Size
2.1 Global Myasthenia Gravis Drugs Market Size: 2021 VS 2028
2.2 Global Myasthenia Gravis Drugs Revenue, Prospects & Forecasts: 2017-2028
2.3 Global Myasthenia Gravis Drugs Sales: 2017-2028
3 Company Landscape
3.1 Top Myasthenia Gravis Drugs Players in Global Market
3.2 Top Global Myasthenia Gravis Drugs Companies Ranked by Revenue
3.3 Global Myasthenia Gravis Drugs Revenue by Companies
3.4 Global Myasthenia Gravis Drugs Sales by Companies
3.5 Global Myasthenia Gravis Drugs Price by Manufacturer (2017-2022)
3.6 Top 3 and Top 5 Myasthenia Gravis Drugs Companies in Global Market, by Revenue in 2021
3.7 Global Manufacturers Myasthenia Gravis Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Myasthenia Gravis Drugs Players in Global Market
3.8.1 List of Global Tier 1 Myasthenia Gravis Drugs Companies
3.8.2 List of Global Tier 2 and Tier 3 Myasthenia Gravis Drugs Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Myasthenia Gravis Drugs Market Size Markets, 2021 & 2028
4.1.2 Anticholinesterases
4.1.3 Immunosuppressants
4.1.4 Intravenous Immune Globulins
4.2 By Type - Global Myasthenia Gravis Drugs Revenue & Forecasts
4.2.1 By Type - Global Myasthenia Gravis Drugs Revenue, 2017-2022
4.2.2 By Type - Global Myasthenia Gravis Drugs Revenue, 2023-2028
4.2.3 By Type - Global Myasthenia Gravis Drugs Revenue Market Share, 2017-2028
4.3 By Type - Global Myasthenia Gravis Drugs Sales & Forecasts
4.3.1 By Type - Global Myasthenia Gravis Drugs Sales, 2017-2022
4.3.2 By Type - Global Myasthenia Gravis Drugs Sales, 2023-2028
4.3.3 By Type - Global Myasthenia Gravis Drugs Sales Market Share, 2017-2028
4.4 By Type - Global Myasthenia Gravis Drugs Price (Manufacturers Selling Prices), 2017-2028
5 Sights By Application
5.1 Overview
5.1.1 By Application - Global Myasthenia Gravis Drugs Market Size, 2021 & 2028
5.1.2 Hospitals
5.1.3 Clinics
5.2 By Application - Global Myasthenia Gravis Drugs Revenue & Forecasts
5.2.1 By Application - Global Myasthenia Gravis Drugs Revenue, 2017-2022
5.2.2 By Application - Global Myasthenia Gravis Drugs Revenue, 2023-2028
5.2.3 By Application - Global Myasthenia Gravis Drugs Revenue Market Share, 2017-2028
5.3 By Application - Global Myasthenia Gravis Drugs Sales & Forecasts
5.3.1 By Application - Global Myasthenia Gravis Drugs Sales, 2017-2022
5.3.2 By Application - Global Myasthenia Gravis Drugs Sales, 2023-2028
5.3.3 By Application - Global Myasthenia Gravis Drugs Sales Market Share, 2017-2028
5.4 By Application - Global Myasthenia Gravis Drugs Price (Manufacturers Selling Prices), 2017-2028
6 Sights by Region
6.1 By Region - Global Myasthenia Gravis Drugs Market Size, 2021 & 2028
6.2 By Region - Global Myasthenia Gravis Drugs Revenue & Forecasts
6.2.1 By Region - Global Myasthenia Gravis Drugs Revenue, 2017-2022
6.2.2 By Region - Global Myasthenia Gravis Drugs Revenue, 2023-2028
6.2.3 By Region - Global Myasthenia Gravis Drugs Revenue Market Share, 2017-2028
6.3 By Region - Global Myasthenia Gravis Drugs Sales & Forecasts
6.3.1 By Region - Global Myasthenia Gravis Drugs Sales, 2017-2022
6.3.2 By Region - Global Myasthenia Gravis Drugs Sales, 2023-2028
6.3.3 By Region - Global Myasthenia Gravis Drugs Sales Market Share, 2017-2028
6.4 North America
6.4.1 By Country - North America Myasthenia Gravis Drugs Revenue, 2017-2028
6.4.2 By Country - North America Myasthenia Gravis Drugs Sales, 2017-2028
6.4.3 US Myasthenia Gravis Drugs Market Size, 2017-2028
6.4.4 Canada Myasthenia Gravis Drugs Market Size, 2017-2028
6.4.5 Mexico Myasthenia Gravis Drugs Market Size, 2017-2028
6.5 Europe
6.5.1 By Country - Europe Myasthenia Gravis Drugs Revenue, 2017-2028
6.5.2 By Country - Europe Myasthenia Gravis Drugs Sales, 2017-2028
6.5.3 Germany Myasthenia Gravis Drugs Market Size, 2017-2028
6.5.4 France Myasthenia Gravis Drugs Market Size, 2017-2028
6.5.5 U.K. Myasthenia Gravis Drugs Market Size, 2017-2028
6.5.6 Italy Myasthenia Gravis Drugs Market Size, 2017-2028
6.5.7 Russia Myasthenia Gravis Drugs Market Size, 2017-2028
6.5.8 Nordic Countries Myasthenia Gravis Drugs Market Size, 2017-2028
6.5.9 Benelux Myasthenia Gravis Drugs Market Size, 2017-2028
6.6 Asia
6.6.1 By Region - Asia Myasthenia Gravis Drugs Revenue, 2017-2028
6.6.2 By Region - Asia Myasthenia Gravis Drugs Sales, 2017-2028
6.6.3 China Myasthenia Gravis Drugs Market Size, 2017-2028
6.6.4 Japan Myasthenia Gravis Drugs Market Size, 2017-2028
6.6.5 South Korea Myasthenia Gravis Drugs Market Size, 2017-2028
6.6.6 Southeast Asia Myasthenia Gravis Drugs Market Size, 2017-2028
6.6.7 India Myasthenia Gravis Drugs Market Size, 2017-2028
6.7 South America
6.7.1 By Country - South America Myasthenia Gravis Drugs Revenue, 2017-2028
6.7.2 By Country - South America Myasthenia Gravis Drugs Sales, 2017-2028
6.7.3 Brazil Myasthenia Gravis Drugs Market Size, 2017-2028
6.7.4 Argentina Myasthenia Gravis Drugs Market Size, 2017-2028
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Myasthenia Gravis Drugs Revenue, 2017-2028
6.8.2 By Country - Middle East & Africa Myasthenia Gravis Drugs Sales, 2017-2028
6.8.3 Turkey Myasthenia Gravis Drugs Market Size, 2017-2028
6.8.4 Israel Myasthenia Gravis Drugs Market Size, 2017-2028
6.8.5 Saudi Arabia Myasthenia Gravis Drugs Market Size, 2017-2028
6.8.6 UAE Myasthenia Gravis Drugs Market Size, 2017-2028
7 Manufacturers & Brands Profiles
7.1 Flamel Technologies
7.1.1 Flamel Technologies Corporate Summary
7.1.2 Flamel Technologies Business Overview
7.1.3 Flamel Technologies Myasthenia Gravis Drugs Major Product Offerings
7.1.4 Flamel Technologies Myasthenia Gravis Drugs Sales and Revenue in Global (2017-2022)
7.1.5 Flamel Technologies Key News
7.2 F. Hoffmann-La Roche
7.2.1 F. Hoffmann-La Roche Corporate Summary
7.2.2 F. Hoffmann-La Roche Business Overview
7.2.3 F. Hoffmann-La Roche Myasthenia Gravis Drugs Major Product Offerings
7.2.4 F. Hoffmann-La Roche Myasthenia Gravis Drugs Sales and Revenue in Global (2017-2022)
7.2.5 F. Hoffmann-La Roche Key News
7.3 Grifols
7.3.1 Grifols Corporate Summary
7.3.2 Grifols Business Overview
7.3.3 Grifols Myasthenia Gravis Drugs Major Product Offerings
7.3.4 Grifols Myasthenia Gravis Drugs Sales and Revenue in Global (2017-2022)
7.3.5 Grifols Key News
7.4 Pfizer
7.4.1 Pfizer Corporate Summary
7.4.2 Pfizer Business Overview
7.4.3 Pfizer Myasthenia Gravis Drugs Major Product Offerings
7.4.4 Pfizer Myasthenia Gravis Drugs Sales and Revenue in Global (2017-2022)
7.4.5 Pfizer Key News
7.5 Takeda
7.5.1 Takeda Corporate Summary
7.5.2 Takeda Business Overview
7.5.3 Takeda Myasthenia Gravis Drugs Major Product Offerings
7.5.4 Takeda Myasthenia Gravis Drugs Sales and Revenue in Global (2017-2022)
7.5.5 Takeda Key News
7.6 Novartis
7.6.1 Novartis Corporate Summary
7.6.2 Novartis Business Overview
7.6.3 Novartis Myasthenia Gravis Drugs Major Product Offerings
7.6.4 Novartis Myasthenia Gravis Drugs Sales and Revenue in Global (2017-2022)
7.6.5 Novartis Key News
7.7 Bausch Health
7.7.1 Bausch Health Corporate Summary
7.7.2 Bausch Health Business Overview
7.7.3 Bausch Health Myasthenia Gravis Drugs Major Product Offerings
7.7.4 Bausch Health Myasthenia Gravis Drugs Sales and Revenue in Global (2017-2022)
7.7.5 Bausch Health Key News
7.8 Alexion Pharmaceuticals
7.8.1 Alexion Pharmaceuticals Corporate Summary
7.8.2 Alexion Pharmaceuticals Business Overview
7.8.3 Alexion Pharmaceuticals Myasthenia Gravis Drugs Major Product Offerings
7.8.4 Alexion Pharmaceuticals Myasthenia Gravis Drugs Sales and Revenue in Global (2017-2022)
7.8.5 Alexion Pharmaceuticals Key News
7.9 Catalyst Pharmaceuticals
7.9.1 Catalyst Pharmaceuticals Corporate Summary
7.9.2 Catalyst Pharmaceuticals Business Overview
7.9.3 Catalyst Pharmaceuticals Myasthenia Gravis Drugs Major Product Offerings
7.9.4 Catalyst Pharmaceuticals Myasthenia Gravis Drugs Sales and Revenue in Global (2017-2022)
7.9.5 Catalyst Pharmaceuticals Key News
7.10 CSL
7.10.1 CSL Corporate Summary
7.10.2 CSL Business Overview
7.10.3 CSL Myasthenia Gravis Drugs Major Product Offerings
7.10.4 CSL Myasthenia Gravis Drugs Sales and Revenue in Global (2017-2022)
7.10.5 CSL Key News
7.11 Curavac
7.11.1 Curavac Corporate Summary
7.11.2 Curavac Myasthenia Gravis Drugs Business Overview
7.11.3 Curavac Myasthenia Gravis Drugs Major Product Offerings
7.11.4 Curavac Myasthenia Gravis Drugs Sales and Revenue in Global (2017-2022)
7.11.5 Curavac Key News
7.12 Cytokinetics
7.12.1 Cytokinetics Corporate Summary
7.12.2 Cytokinetics Myasthenia Gravis Drugs Business Overview
7.12.3 Cytokinetics Myasthenia Gravis Drugs Major Product Offerings
7.12.4 Cytokinetics Myasthenia Gravis Drugs Sales and Revenue in Global (2017-2022)
7.12.5 Cytokinetics Key News
7.13 Galencia
7.13.1 Galencia Corporate Summary
7.13.2 Galencia Myasthenia Gravis Drugs Business Overview
7.13.3 Galencia Myasthenia Gravis Drugs Major Product Offerings
7.13.4 Galencia Myasthenia Gravis Drugs Sales and Revenue in Global (2017-2022)
7.13.5 Galencia Key News
7.14 GlaxoSmithKline
7.14.1 GlaxoSmithKline Corporate Summary
7.14.2 GlaxoSmithKline Business Overview
7.14.3 GlaxoSmithKline Myasthenia Gravis Drugs Major Product Offerings
7.14.4 GlaxoSmithKline Myasthenia Gravis Drugs Sales and Revenue in Global (2017-2022)
7.14.5 GlaxoSmithKline Key News
7.15 Lupin Pharmaceuticals
7.15.1 Lupin Pharmaceuticals Corporate Summary
7.15.2 Lupin Pharmaceuticals Business Overview
7.15.3 Lupin Pharmaceuticals Myasthenia Gravis Drugs Major Product Offerings
7.15.4 Lupin Pharmaceuticals Myasthenia Gravis Drugs Sales and Revenue in Global (2017-2022)
7.15.5 Lupin Pharmaceuticals Key News
7.16 Mitsubishi Tanabe Pharma
7.16.1 Mitsubishi Tanabe Pharma Corporate Summary
7.16.2 Mitsubishi Tanabe Pharma Business Overview
7.16.3 Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Major Product Offerings
7.16.4 Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Sales and Revenue in Global (2017-2022)
7.16.5 Mitsubishi Tanabe Pharma Key News
8 Global Myasthenia Gravis Drugs Production Capacity, Analysis
8.1 Global Myasthenia Gravis Drugs Production Capacity, 2017-2028
8.2 Myasthenia Gravis Drugs Production Capacity of Key Manufacturers in Global Market
8.3 Global Myasthenia Gravis Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Myasthenia Gravis Drugs Supply Chain Analysis
10.1 Myasthenia Gravis Drugs Industry Value Chain
10.2 Myasthenia Gravis Drugs Upstream Market
10.3 Myasthenia Gravis Drugs Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Myasthenia Gravis Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Key Players of Myasthenia Gravis Drugs in Global Market
Table 2. Top Myasthenia Gravis Drugs Players in Global Market, Ranking by Revenue (2021)
Table 3. Global Myasthenia Gravis Drugs Revenue by Companies, (US$, Mn), 2017-2022
Table 4. Global Myasthenia Gravis Drugs Revenue Share by Companies, 2017-2022
Table 5. Global Myasthenia Gravis Drugs Sales by Companies, (MT), 2017-2022
Table 6. Global Myasthenia Gravis Drugs Sales Share by Companies, 2017-2022
Table 7. Key Manufacturers Myasthenia Gravis Drugs Price (2017-2022) & (USD/Kg)
Table 8. Global Manufacturers Myasthenia Gravis Drugs Product Type
Table 9. List of Global Tier 1 Myasthenia Gravis Drugs Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Myasthenia Gravis Drugs Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type ? Global Myasthenia Gravis Drugs Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Global Myasthenia Gravis Drugs Revenue (US$, Mn), 2017-2022
Table 13. By Type - Global Myasthenia Gravis Drugs Revenue (US$, Mn), 2023-2028
Table 14. By Type - Global Myasthenia Gravis Drugs Sales (MT), 2017-2022
Table 15. By Type - Global Myasthenia Gravis Drugs Sales (MT), 2023-2028
Table 16. By Application ? Global Myasthenia Gravis Drugs Revenue, (US$, Mn), 2021 & 2028
Table 17. By Application - Global Myasthenia Gravis Drugs Revenue (US$, Mn), 2017-2022
Table 18. By Application - Global Myasthenia Gravis Drugs Revenue (US$, Mn), 2023-2028
Table 19. By Application - Global Myasthenia Gravis Drugs Sales (MT), 2017-2022
Table 20. By Application - Global Myasthenia Gravis Drugs Sales (MT), 2023-2028
Table 21. By Region ? Global Myasthenia Gravis Drugs Revenue, (US$, Mn), 2021 VS 2028
Table 22. By Region - Global Myasthenia Gravis Drugs Revenue (US$, Mn), 2017-2022
Table 23. By Region - Global Myasthenia Gravis Drugs Revenue (US$, Mn), 2023-2028
Table 24. By Region - Global Myasthenia Gravis Drugs Sales (MT), 2017-2022
Table 25. By Region - Global Myasthenia Gravis Drugs Sales (MT), 2023-2028
Table 26. By Country - North America Myasthenia Gravis Drugs Revenue, (US$, Mn), 2017-2022
Table 27. By Country - North America Myasthenia Gravis Drugs Revenue, (US$, Mn), 2023-2028
Table 28. By Country - North America Myasthenia Gravis Drugs Sales, (MT), 2017-2022
Table 29. By Country - North America Myasthenia Gravis Drugs Sales, (MT), 2023-2028
Table 30. By Country - Europe Myasthenia Gravis Drugs Revenue, (US$, Mn), 2017-2022
Table 31. By Country - Europe Myasthenia Gravis Drugs Revenue, (US$, Mn), 2023-2028
Table 32. By Country - Europe Myasthenia Gravis Drugs Sales, (MT), 2017-2022
Table 33. By Country - Europe Myasthenia Gravis Drugs Sales, (MT), 2023-2028
Table 34. By Region - Asia Myasthenia Gravis Drugs Revenue, (US$, Mn), 2017-2022
Table 35. By Region - Asia Myasthenia Gravis Drugs Revenue, (US$, Mn), 2023-2028
Table 36. By Region - Asia Myasthenia Gravis Drugs Sales, (MT), 2017-2022
Table 37. By Region - Asia Myasthenia Gravis Drugs Sales, (MT), 2023-2028
Table 38. By Country - South America Myasthenia Gravis Drugs Revenue, (US$, Mn), 2017-2022
Table 39. By Country - South America Myasthenia Gravis Drugs Revenue, (US$, Mn), 2023-2028
Table 40. By Country - South America Myasthenia Gravis Drugs Sales, (MT), 2017-2022
Table 41. By Country - South America Myasthenia Gravis Drugs Sales, (MT), 2023-2028
Table 42. By Country - Middle East & Africa Myasthenia Gravis Drugs Revenue, (US$, Mn), 2017-2022
Table 43. By Country - Middle East & Africa Myasthenia Gravis Drugs Revenue, (US$, Mn), 2023-2028
Table 44. By Country - Middle East & Africa Myasthenia Gravis Drugs Sales, (MT), 2017-2022
Table 45. By Country - Middle East & Africa Myasthenia Gravis Drugs Sales, (MT), 2023-2028
Table 46. Flamel Technologies Corporate Summary
Table 47. Flamel Technologies Myasthenia Gravis Drugs Product Offerings
Table 48. Flamel Technologies Myasthenia Gravis Drugs Sales (MT), Revenue (US$, Mn) and Average Price (USD/Kg) (2017-2022)
Table 49. F. Hoffmann-La Roche Corporate Summary
Table 50. F. Hoffmann-La Roche Myasthenia Gravis Drugs Product Offerings
Table 51. F. Hoffmann-La Roche Myasthenia Gravis Drugs Sales (MT), Revenue (US$, Mn) and Average Price (USD/Kg) (2017-2022)
Table 52. Grifols Corporate Summary
Table 53. Grifols Myasthenia Gravis Drugs Product Offerings
Table 54. Grifols Myasthenia Gravis Drugs Sales (MT), Revenue (US$, Mn) and Average Price (USD/Kg) (2017-2022)
Table 55. Pfizer Corporate Summary
Table 56. Pfizer Myasthenia Gravis Drugs Product Offerings
Table 57. Pfizer Myasthenia Gravis Drugs Sales (MT), Revenue (US$, Mn) and Average Price (USD/Kg) (2017-2022)
Table 58. Takeda Corporate Summary
Table 59. Takeda Myasthenia Gravis Drugs Product Offerings
Table 60. Takeda Myasthenia Gravis Drugs Sales (MT), Revenue (US$, Mn) and Average Price (USD/Kg) (2017-2022)
Table 61. Novartis Corporate Summary
Table 62. Novartis Myasthenia Gravis Drugs Product Offerings
Table 63. Novartis Myasthenia Gravis Drugs Sales (MT), Revenue (US$, Mn) and Average Price (USD/Kg) (2017-2022)
Table 64. Bausch Health Corporate Summary
Table 65. Bausch Health Myasthenia Gravis Drugs Product Offerings
Table 66. Bausch Health Myasthenia Gravis Drugs Sales (MT), Revenue (US$, Mn) and Average Price (USD/Kg) (2017-2022)
Table 67. Alexion Pharmaceuticals Corporate Summary
Table 68. Alexion Pharmaceuticals Myasthenia Gravis Drugs Product Offerings
Table 69. Alexion Pharmaceuticals Myasthenia Gravis Drugs Sales (MT), Revenue (US$, Mn) and Average Price (USD/Kg) (2017-2022)
Table 70. Catalyst Pharmaceuticals Corporate Summary
Table 71. Catalyst Pharmaceuticals Myasthenia Gravis Drugs Product Offerings
Table 72. Catalyst Pharmaceuticals Myasthenia Gravis Drugs Sales (MT), Revenue (US$, Mn) and Average Price (USD/Kg) (2017-2022)
Table 73. CSL Corporate Summary
Table 74. CSL Myasthenia Gravis Drugs Product Offerings
Table 75. CSL Myasthenia Gravis Drugs Sales (MT), Revenue (US$, Mn) and Average Price (USD/Kg) (2017-2022)
Table 76. Curavac Corporate Summary
Table 77. Curavac Myasthenia Gravis Drugs Product Offerings
Table 78. Curavac Myasthenia Gravis Drugs Sales (MT), Revenue (US$, Mn) and Average Price (USD/Kg) (2017-2022)
Table 79. Cytokinetics Corporate Summary
Table 80. Cytokinetics Myasthenia Gravis Drugs Product Offerings
Table 81. Cytokinetics Myasthenia Gravis Drugs Sales (MT), Revenue (US$, Mn) and Average Price (USD/Kg) (2017-2022)
Table 82. Galencia Corporate Summary
Table 83. Galencia Myasthenia Gravis Drugs Product Offerings
Table 84. Galencia Myasthenia Gravis Drugs Sales (MT), Revenue (US$, Mn) and Average Price (USD/Kg) (2017-2022)
Table 85. GlaxoSmithKline Corporate Summary
Table 86. GlaxoSmithKline Myasthenia Gravis Drugs Product Offerings
Table 87. GlaxoSmithKline Myasthenia Gravis Drugs Sales (MT), Revenue (US$, Mn) and Average Price (USD/Kg) (2017-2022)
Table 88. Lupin Pharmaceuticals Corporate Summary
Table 89. Lupin Pharmaceuticals Myasthenia Gravis Drugs Product Offerings
Table 90. Lupin Pharmaceuticals Myasthenia Gravis Drugs Sales (MT), Revenue (US$, Mn) and Average Price (USD/Kg) (2017-2022)
Table 91. Mitsubishi Tanabe Pharma Corporate Summary
Table 92. Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Product Offerings
Table 93. Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Sales (MT), Revenue (US$, Mn) and Average Price (USD/Kg) (2017-2022)
Table 94. Myasthenia Gravis Drugs Production Capacity (MT) of Key Manufacturers in Global Market, 2020-2022 (MT)
Table 95. Global Myasthenia Gravis Drugs Capacity Market Share of Key Manufacturers, 2020-2022
Table 96. Global Myasthenia Gravis Drugs Production by Region, 2017-2022 (MT)
Table 97. Global Myasthenia Gravis Drugs Production by Region, 2023-2028 (MT)
Table 98. Myasthenia Gravis Drugs Market Opportunities & Trends in Global Market
Table 99. Myasthenia Gravis Drugs Market Drivers in Global Market
Table 100. Myasthenia Gravis Drugs Market Restraints in Global Market
Table 101. Myasthenia Gravis Drugs Raw Materials
Table 102. Myasthenia Gravis Drugs Raw Materials Suppliers in Global Market
Table 103. Typical Myasthenia Gravis Drugs Downstream
Table 104. Myasthenia Gravis Drugs Downstream Clients in Global Market
Table 105. Myasthenia Gravis Drugs Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Myasthenia Gravis Drugs Segment by Type
Figure 2. Myasthenia Gravis Drugs Segment by Application
Figure 3. Global Myasthenia Gravis Drugs Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Myasthenia Gravis Drugs Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Myasthenia Gravis Drugs Revenue, 2017-2028 (US$, Mn)
Figure 7. Myasthenia Gravis Drugs Sales in Global Market: 2017-2028 (MT)
Figure 8. The Top 3 and 5 Players Market Share by Myasthenia Gravis Drugs Revenue in 2021
Figure 9. By Type - Global Myasthenia Gravis Drugs Sales Market Share, 2017-2028
Figure 10. By Type - Global Myasthenia Gravis Drugs Revenue Market Share, 2017-2028
Figure 11. By Type - Global Myasthenia Gravis Drugs Price (USD/Kg), 2017-2028
Figure 12. By Application - Global Myasthenia Gravis Drugs Sales Market Share, 2017-2028
Figure 13. By Application - Global Myasthenia Gravis Drugs Revenue Market Share, 2017-2028
Figure 14. By Application - Global Myasthenia Gravis Drugs Price (USD/Kg), 2017-2028
Figure 15. By Region - Global Myasthenia Gravis Drugs Sales Market Share, 2017-2028
Figure 16. By Region - Global Myasthenia Gravis Drugs Revenue Market Share, 2017-2028
Figure 17. By Country - North America Myasthenia Gravis Drugs Revenue Market Share, 2017-2028
Figure 18. By Country - North America Myasthenia Gravis Drugs Sales Market Share, 2017-2028
Figure 19. US Myasthenia Gravis Drugs Revenue, (US$, Mn), 2017-2028
Figure 20. Canada Myasthenia Gravis Drugs Revenue, (US$, Mn), 2017-2028
Figure 21. Mexico Myasthenia Gravis Drugs Revenue, (US$, Mn), 2017-2028
Figure 22. By Country - Europe Myasthenia Gravis Drugs Revenue Market Share, 2017-2028
Figure 23. By Country - Europe Myasthenia Gravis Drugs Sales Market Share, 2017-2028
Figure 24. Germany Myasthenia Gravis Drugs Revenue, (US$, Mn), 2017-2028
Figure 25. France Myasthenia Gravis Drugs Revenue, (US$, Mn), 2017-2028
Figure 26. U.K. Myasthenia Gravis Drugs Revenue, (US$, Mn), 2017-2028
Figure 27. Italy Myasthenia Gravis Drugs Revenue, (US$, Mn), 2017-2028
Figure 28. Russia Myasthenia Gravis Drugs Revenue, (US$, Mn), 2017-2028
Figure 29. Nordic Countries Myasthenia Gravis Drugs Revenue, (US$, Mn), 2017-2028
Figure 30. Benelux Myasthenia Gravis Drugs Revenue, (US$, Mn), 2017-2028
Figure 31. By Region - Asia Myasthenia Gravis Drugs Revenue Market Share, 2017-2028
Figure 32. By Region - Asia Myasthenia Gravis Drugs Sales Market Share, 2017-2028
Figure 33. China Myasthenia Gravis Drugs Revenue, (US$, Mn), 2017-2028
Figure 34. Japan Myasthenia Gravis Drugs Revenue, (US$, Mn), 2017-2028
Figure 35. South Korea Myasthenia Gravis Drugs Revenue, (US$, Mn), 2017-2028
Figure 36. Southeast Asia Myasthenia Gravis Drugs Revenue, (US$, Mn), 2017-2028
Figure 37. India Myasthenia Gravis Drugs Revenue, (US$, Mn), 2017-2028
Figure 38. By Country - South America Myasthenia Gravis Drugs Revenue Market Share, 2017-2028
Figure 39. By Country - South America Myasthenia Gravis Drugs Sales Market Share, 2017-2028
Figure 40. Brazil Myasthenia Gravis Drugs Revenue, (US$, Mn), 2017-2028
Figure 41. Argentina Myasthenia Gravis Drugs Revenue, (US$, Mn), 2017-2028
Figure 42. By Country - Middle East & Africa Myasthenia Gravis Drugs Revenue Market Share, 2017-2028
Figure 43. By Country - Middle East & Africa Myasthenia Gravis Drugs Sales Market Share, 2017-2028
Figure 44. Turkey Myasthenia Gravis Drugs Revenue, (US$, Mn), 2017-2028
Figure 45. Israel Myasthenia Gravis Drugs Revenue, (US$, Mn), 2017-2028
Figure 46. Saudi Arabia Myasthenia Gravis Drugs Revenue, (US$, Mn), 2017-2028
Figure 47. UAE Myasthenia Gravis Drugs Revenue, (US$, Mn), 2017-2028
Figure 48. Global Myasthenia Gravis Drugs Production Capacity (MT), 2017-2028
Figure 49. The Percentage of Production Myasthenia Gravis Drugs by Region, 2021 VS 2028
Figure 50. Myasthenia Gravis Drugs Industry Value Chain
Figure 51. Marketing Channels
